Comparison of oral absorption and bioavailability of drugs between monkey and human

被引:90
作者
Chiou, WL [1 ]
Buehler, PW [1 ]
机构
[1] Univ Illinois, Dept Pharmaceut & Pharmacodynam MC 865, Coll Pharm, Chicago, IL 60612 USA
关键词
drug absorption; drug bioavailability; first-pass metabolism; monkey; pharmacokinetics; plasma clearance;
D O I
10.1023/A:1016169202830
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To compare the oral absorption and bioavailability of numerous drugs with a wide variety of physicochemical and pharmacological properties between humans and monkeys and to explore potential reasons for the findings. Methods. Data for fraction of dose absorbed (F-a) and oral absolute bioavailability (F) were obtained by an extensive Medline database search. Inclusion and exclusion criteria were the same as those reported in our previous studies. A total of 43 and 35 drugs were selected for F-a and F comparison, respectively. The time to reach peak concentration (t(max)), total clearance, and nonrenal clearance were evaluated for 15, 28, and 13 drugs, respectively. Results. F-a values in monkeys were similar or identical to those in humans. Additionally, similar t(max) values were seen in monkeys and humans at comparable doses, thus indicating comparable absorption kinetics between the two species. Conversely, F values in monkeys were generally lower with coumarin being a marked exception. Both total and nonrenal clearances were evaluated and found to be generally greater in monkeys, supporting a generally higher first-pass metabolism and lower F in this species. This was also supported by published data suggesting greater in vitro hepatic drug metabolism for monkeys as compared to humans. Conclusions. Monkeys appear to be a good predictor of F-a in humans. However, a generally lower F makes monkeys a potentially poor predictor of human F. Higher reported metabolic clearances and hepatic enzyme activities in monkeys may account for this observation.
引用
收藏
页码:868 / 874
页数:7
相关论文
共 33 条
  • [21] Kuroda T, 2000, BIOL PHARM BULL, V23, P334
  • [22] LIN JH, 1995, DRUG METAB DISPOS, V23, P1008
  • [23] Lin JH, 1996, DRUG METAB DISPOS, V24, P1111
  • [24] *MED EC CO, 2001, PHYS DESK REF
  • [25] PRICHARD L, 1995, DRUG METAB DISPOS, V23, P1253
  • [26] RITSCHEL WA, 1976, ARZNEIMITTEL-FORSCH, V26, P1382
  • [27] RITSCHEL WA, 1991, METHOD FIND EXP CLIN, V13, P697
  • [28] RITSCHEL WA, 1988, ARZNEIMITTEL-FORSCH, V38-2, P1619
  • [29] SHARER JE, 1995, DRUG METAB DISPOS, V23, P1231
  • [30] Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans
    Shimada, T
    Mimura, M
    Inoue, K
    Nakamura, S
    Oda, H
    Ohmori, S
    Yamazaki, H
    [J]. ARCHIVES OF TOXICOLOGY, 1997, 71 (06) : 401 - 408